ReportGem ReportGem

U.S. COMPANY FILING

ALNYLAM PHARMACEUTICALS, INC. — Form 10-Q filed 2026-07-30

Filed: 2026-07-30Company: ALNYLAM PHARMACEUTICALS, INC.Ticker: ALNYExchange: NasdaqForm: 10-QReport period: 2026-06-30SEC accession: 0001178670-26-000062Event: earningsMateriality: 85

Filing text preview

Alnylam reported Q2 2026 revenue of $1.29B, up 67% YoY, and net income of $164M, a turnaround from a loss. H1 revenue grew 80% to $2.46B. Strong AMVUTTRA sales drove growth, but COGS increased. The company reaffirmed its 2030 strategy and noted a possible partial reversal of U.S. valuation allowance.

This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.

Open filing record

Related research and intelligence

Official SEC filing2026-07-308-K2026-07-30 · 8-K10-Q2026-04-30 · 10-Q8-K2026-04-30 · 8-K10-K2026-02-12 · 10-K8-K2026-02-12 · 8-K8-K2026-01-12 · 8-K